Revo Spa News - REVO99

Europe Approves Novel Australian Drug Developed for Rare Sun Disease

The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory...

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study Primary endpoint shows a strong statistical trend in pain-free...

Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has submitted a marketing...

Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria ...

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise...

EMA acknowledges Clinuvel’s novel drug filing in Europe in 2011

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it held a constructive...

Successful Drug Trial Results for Light Intolerant 'Shadow Jumpers'

A new Australian drug has been shown to assist in protecting patients with a rare genetic disorder that makes their skin toxic to...

Clinuvel Unveils SCENESSE® Following European Brand Approval

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the European Medicines Agency (EMA...

Preliminary Results in Clinuvel’s Phase III Porphyria Trial

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has obtained promising 4-months...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Revo Spa (REVO99)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

REVO99 News

Europe Approves Novel Australian Drug Developed for Rare Sun Disease

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study

Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)

Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria ...

EMA acknowledges Clinuvel’s novel drug filing in Europe in 2011

Successful Drug Trial Results for Light Intolerant 'Shadow Jumpers'

Clinuvel Unveils SCENESSE® Following European Brand Approval

Preliminary Results in Clinuvel’s Phase III Porphyria Trial

REVO99 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Revo Spa (REVO99) News

Revo Spa (REVO99)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

REVO99 News

Europe Approves Novel Australian Drug Developed for Rare Sun Disease

Clinical Significance and Benefit from SCENESSE(R) in US Phase III EPP study

Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)

Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria ...

EMA acknowledges Clinuvel’s novel drug filing in Europe in 2011

Successful Drug Trial Results for Light Intolerant 'Shadow Jumpers'

Clinuvel Unveils SCENESSE® Following European Brand Approval

Preliminary Results in Clinuvel’s Phase III Porphyria Trial

REVO99 Discussion

Your Recent History